scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1026106232 |
P356 | DOI | 10.1038/SJ.TPJ.6500434 |
P698 | PubMed publication ID | 17224914 |
P50 | author | Timothy Synold | Q78536675 |
P2093 | author name string | X Li | |
H L McLeod | |||
C R King | |||
P Frankel | |||
G Somlo | |||
W D Shannon | |||
S Marsh | |||
P2860 | cites work | mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy | Q27824862 |
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux | Q28186424 | ||
The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue | Q28214188 | ||
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition | Q33206580 | ||
??? | Q28366611 | ||
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience | Q35783180 | ||
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention | Q36425250 | ||
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer | Q36623452 | ||
ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins | Q40568208 | ||
Increased transcriptional activity of the CYP3A4*1B promoter variant | Q40607751 | ||
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism | Q40760221 | ||
Identification of functionally variant MDR1 alleles among European Americans and African Americans | Q43705904 | ||
Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme | Q44183995 | ||
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype | Q44960521 | ||
CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy | Q45185406 | ||
Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer | Q45285506 | ||
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population | Q45712938 | ||
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations | Q46464296 | ||
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity | Q46923500 | ||
Catalytic properties of polymorphic human cytochrome P450 1B1 variants | Q50125350 | ||
Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. | Q54684767 | ||
CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer | Q61608137 | ||
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes | Q63241956 | ||
Expression of cytochrome P450 CYP1B1 in breast cancer | Q71816201 | ||
Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls | Q73548231 | ||
Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol | Q73914185 | ||
The genetic determinants of the CYP3A5 polymorphism | Q77341911 | ||
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis | Q79297590 | ||
Drug pathways: moving beyond single gene pharmacogenetics | Q79768663 | ||
ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer | Q79834519 | ||
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel | Q81506947 | ||
Taxane pharmacogenetics | Q88759446 | ||
P433 | issue | 5 | |
P921 | main subject | breast cancer | Q128581 |
paclitaxel | Q423762 | ||
P304 | page(s) | 362-365 | |
P577 | publication date | 2007-01-16 | |
P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
P1476 | title | Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer | |
P478 | volume | 7 |
Q47157497 | Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results |
Q34936845 | CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro |
Q37055326 | CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel |
Q33704464 | Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. |
Q35003605 | Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies |
Q86451186 | Differentially expressed proteins in human MCF-7 breast cancer cells sensitive and resistant to paclitaxel |
Q35823740 | ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors |
Q36550926 | Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer |
Q37811967 | In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2) |
Q83390482 | In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance |
Q37128654 | Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice |
Q42549809 | Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202). |
Q37788732 | Level of evidence for therapeutic drug monitoring of taxanes |
Q34095952 | Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. |
Q35781414 | Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. |
Q38756385 | Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. |
Q91644097 | Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study |
Q35584977 | Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism |
Q90298807 | Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure |
Q38130410 | PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. |
Q53272686 | Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. |
Q36441485 | Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management |
Q37684533 | Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy |
Q27006783 | Pharmacogenomics of breast cancer therapy: an update |
Q36304316 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes |
Q37187663 | Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. |
Q37686610 | Population-based differences in treatment outcome following anticancer drug therapies. |
Q90568559 | Single-nucleotide polymorphisms and mRNA expression of CYP1B1 influence treatment response in triple negative breast cancer patients undergoing chemotherapy |
Q34390370 | Taxane pathway |
Q58697844 | VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters |